http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
정성희(Sung Hee Jung),정훈용(Hwoon Yong Jung),김태원(Tae Won Kim),김청수(Choung Soo Kim),강경훈(Gyeong Hoon Kang),형철호(Chul Ho Hyung),명승재(Seung Jae Myung),양석균(Suk Kyun Yang),홍원선(Weon Seon Hong),김진호(Jin Ho Kim),민영일(Yo 대한소화기학회 2002 대한소화기학회지 Vol.39 No.3
Background/Aims: Metastatic urinary bladder cancer from a distant organ is unusual. The aim of this study was to analyze clinical characteristics of bladder metastases from stomach cancer. Methods: We reviewed the medical records of 14 patients with metastatic bladder cancer from stomach cancer who admitted at Asan Medical Center between June 1989 and April 2001. Results: The mean age was 47.8 (31-61) years. Nine patients were male and 5 patients female. Mean duration between diagnosis of metastatic bladder cancer and the onset of stomach cancer was 19.7 months (0-40). The most common symptom was hematuria (9 cases), followed by dysuria, frequency, and flank pain. Patients underwent CT scan, urine cytology, IVP, and cystoscopy to evaluate metastasis of the urinary bladder. The locations of metastatic urinary bladder cancer were lateral wall (n=4), dome (n=3), posterior wall (n=3), trigone and dome (n=1), uretero-vesical junction (n=1), and entire bladder (n=2). Three patients underwent transurethral resection and one patient took radical cystectomy. Mean survival duration was 5 months (2-11 months). Conclusions: When urologic symptoms newly develop in patients with stomach cancer, metastasis to the urogenital organs should be considered. (Korean J Gastroenterol 2002;39:173-178)
비혈연간 조혈모세포이식 후 재발한 만성골수성백혈병에서 Gleevec에 의한 완전관해 및 공여자 조혈 재건 1예
박사라,김우건,이제환,최성준,형철호,손희정,강혜진,지형석,이정신,이규형 대한조혈모세포이식학회 2002 대한조혈모세포이식학회지 Vol.7 No.2
저자들은 만성골수성백혈병으로 동종 골수이식 후 림프구성급성전환으로 재발한 환자에서, Gleevec 투약 후 DLI (donor lymphocyte infusion) 없이 공여자 조혈(donor hematopoiesis)의 재건이 이루어지고, 세포유전학적, 분자생물학적 기준에서 모두 완전관해에 이르고, 12개월째 관해를 유지하고 있는 환자를 경험하였기에 이를 보고하는 바이다. 본례의 환자에서 Gleevec은 동종 골수이식 후 급성전환기로 재발한 환자에서도 매우 효과적인 것으로 나타났다. Gleevec은 동종 골수이식 후 재발한 만성골수성백혈병에서 Interferon-α, DLI, 2차골수이식 등 기존의 치료의 문제점을 보완할 수 있는 유용한 치료방법으로 사용될 수 있을 것으로 생각되며, 이의 장기적 치료효과의 평가와 기존치료와의 병합요법의 유용성 등에 대한 향후 연구가 필요할 것으로 생각된다. We report a 32-year old woman with chronic myelongenous leukemia (CML) in lymphoid blast crisis, who underwent allogenic bone marrow transplantation (BMT) from HLA phenotype full mached unrelated donor. Her disease relapsed into full-blown blast crisis. Upon treatment with gleevec, she achieved immediate remission of leukemia as well as the donor type hematopoiesis without donor lymphocyte infusion (DLI). Our case suggests the high effectiveness of gleevec in CML relapsed after allogeneic BMT. Further studies are needed to define the role of gleevec (with or without DLI) in the management of CML relapsed after allogeneic BMT.